Aarti Drugs is currently trading at Rs. 473.55, up by 3.25 points or 0.69% from its previous closing of Rs. 470.30 on the BSE.
The scrip opened at Rs. 465.00 and has touched a high and low of Rs. 476.00 and Rs. 464.45 respectively. So far 6317 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 511.65 on 06-Oct-2022 and a 52 week low of Rs. 310.80 on 20-Mar-2023.
Last one week high and low of the scrip stood at Rs. 476.00 and Rs. 456.85 respectively. The current market cap of the company is Rs. 4403.59 crore.
The promoters holding in the company stood at 59.58%, while Institutions and Non-Institutions held 6.03% and 34.39% respectively.
Aarti Drugs has won Pharmexcil Outstanding Exports Award 2021-2022. The company has received Export Performance Award – API & Intermediaries Gold Star for the year 2021-22 on July 5, 2023, in recognition of commendable contribution to the pharmaceutical export of India.
The awards were presented during the ‘iPHEX 9th edition of Indian Pharmaceutical Exhibition’ organized by the Pharmaceuticals Export Promotion Council (Pharmexcil) and sponsored by Department of Commerce & Industry, Government of India where all the major India Pharmaceutical companies had participated.
The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: